Download presentation
Presentation is loading. Please wait.
Published byDuane Nichols Modified over 9 years ago
1
Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto EHJ Volume 31(1):17-28 January 1, 2010 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
2
Sites of action of current and emerging antithrombotic drugs and antiplatelet agents. Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
3
Intracellular signalling pathways and phenotypic effects mediated by PAR-1 activation by thrombin in platelets. Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
4
Role of thrombin-mediated PAR-1 signalling in haemostasis vs. thrombosis: rationale for PAR-1 antagonist.38 In addition to activating PARs on platelets, thrombin facilitates fibrin formation and protein C activation. Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
5
PAR-1 antagonists in clinical development. Dominick J. Angiolillo et al. Eur Heart J 2010;31:17-28 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.